Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

September’s top stories: GSK-Theravance COPD study, AstraZeneca cUTI results

GlaxoSmithKline (GSK) and Theravance reported the initial results of SUMMIT COPD survival study, AstraZeneca announced positive Phase III results of CAZ-AVI in patients with cUTI, and Boehringer and Lilly's diabetes drug Jardiance showed reduction in cardiovascular risk. Drugdevelopment-technology.com wraps up key headlines from September.

Go Top